secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001104659-23-116327
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio presents interim Phase 2b HBV003 and Phase 2a AB-729-202 data for VTP-300 in chronic HBV at AASLD
--------------------------------------------------------------------------------

- In HBV003, 31% of participants with screening HBsAg ≤200 IU/mL had >1 log HBsAg reductions.
- In AB-729-202, all VTP-300 treated patients maintained HBsAg <100 IU/mL through week 48; 60% maintained <10 IU/mL.
- Seven HBV003 participants met criteria for NUC discontinuation; three discontinued NUC therapy.
- No treatment-related serious adverse events were reported in either trial.
- Data presented in collaboration with Arbutus Biopharma (ABUS) for imdusiran plus VTP-300 combination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000110465923116327/0001104659-23-116327-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000110465923116327/tm2330270d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-116327

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer